[ad_1]
Vaccine stocks fell on Monday after a real-world study showed Modern(MRNA) and PfizerThe two-dose coronavirus vaccines of PFE are 80% effective after the first dose.
X
The news was released during a White House press briefing in which the director of the Centers for Disease Control and Prevention, Rochelle Walensky, expressed her “recurring sense of impending doom.” Covid-19 cases over the past week have increased 10.6% in the past seven days.
Hospital admissions and deaths are also on the rise – up 4.2% and 2.6%, respectively, over the past week, Walensky said at the briefing. Walensky became emotional during the briefing, urging Americans to “hang on a little longer” and get the shot.
“We have so much to look forward to, so much promise and potential from where we are at and so much to hope for, but right now I’m scared,” she said.
In response, Moderna vaccine stocks and Novavax (NVAX) overturned. Moderna stock fell 7.4% to 123.42. Novavax stock slumped 4.6%, falling to 173.75. But BioNTech(BNTX) reversed its previous decline, rising by a fraction to 95.91. BioNTech is Pfizer’s Covid vaccine partner.
Vaccine stocks collapse
Walensky warned of a potential fourth increase in Covid-19 cases. But she offered some hope – and positive news for vaccine stocks. A CDC study of 3,950 essential health workers and workers found that messenger RNA vaccines were 80% effective after the first dose.
After the second dose, the efficacy against Covid-19 increases to 90%.
Both figures are lower than what Pfizer / BioNTech and Moderna reported in their clinical studies. In testing, Pfizer said its vaccine was 95% effective in blocking the virus. Moderna said his vaccine was 94.1% effective. The two vaccine stocks have rallied to the results of their end-stage testing.
Vaccines are only two out of three authorized for emergency use in the United States Johnson & johnsonThe (JNJ) vaccine is also cleared for emergency use. It was found to be 66% effective overall and 72% effective in the United States, J&J said of its Phase 3 clinical trial.
“We have come such a long way,” Walensky said. “Three groundbreaking historic and scientific vaccines and we are deploying them very quickly.”
‘Not quite yet’
Walensky urged Americans to avoid travel unless it is essential. The CDC is also monitoring viral variants that could challenge the effectiveness of vaccines. She noted that some states were opening up too quickly – a move that could lead to a fourth increase in the number of Covid-19 cases.
“I want so badly to be done,” she said. “I know you all want to be done so badly. We’re almost there, but not quite yet.
Overall, vaccine stocks have increased this year. Novavax stock has climbed nearly 56% at Monday’s close. Moderna shares are up more than 18%. BioNTech shares have risen nearly 18% over the same period.
Follow Allison Gatlin on Twitter at @IBD_AGatlin.
YOU MAY ALSO LIKE:
Unique stock emerges after acquittal of gene therapy in cancer diagnosis
Does AstraZeneca Stock A Buy As Shares Yo-Yo On Covid Vaccine Woes?
Find winning stocks with MarketSmith pattern recognition and custom screens
Looking for the next Apple or Amazon? Start with these S&P 500 beat lists
Stocks to buy and watch: major IPOs, large and small caps, growth stocks
[ad_2]
Source link